These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 35569438)

  • 21. Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK + non-small cell lung cancer (ALTA-1L).
    Garcia Campelo MR; Lin HM; Zhu Y; Pérol M; Jahanzeb M; Popat S; Zhang P; Camidge DR
    Lung Cancer; 2021 May; 155():68-77. PubMed ID: 33744781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-c30): validation of English version in Singapore.
    Luo N; Fones CS; Lim SE; Xie F; Thumboo J; Li SC
    Qual Life Res; 2005 May; 14(4):1181-6. PubMed ID: 16041912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
    Musoro JZ; Coens C; Greimel E; King MT; Sprangers MAG; Nordin A; van Dorst EBL; Groenvold M; Cocks K; Velikova G; Flechtner HH; Bottomley A;
    Gynecol Oncol; 2020 Nov; 159(2):515-521. PubMed ID: 32972782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The EORTC QLQ-C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the "Real-World": Results from the Population-Based PROFILES Registry.
    Husson O; de Rooij BH; Kieffer J; Oerlemans S; Mols F; Aaronson NK; van der Graaf WTA; van de Poll-Franse LV
    Oncologist; 2020 Apr; 25(4):e722-e732. PubMed ID: 32297435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does it matter how we evaluate HRQOL? Longitudinal comparison of the EORTC QLQ-C30/QLQ-OG25 and FACT-E.
    Darling GE; Sulman J; Espin-Garcia O; Trudel JG; Atenafu EG; Kidane B
    J Cancer Surviv; 2021 Aug; 15(4):641-650. PubMed ID: 33106994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Normative data for the EORTC QLQ-C30 from the Austrian general population.
    Lehmann J; Giesinger JM; Nolte S; Sztankay M; Wintner LM; Liegl G; Rose M; Holzner B;
    Health Qual Life Outcomes; 2020 Aug; 18(1):275. PubMed ID: 32787854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EORTC QLQ-C30 normative data for the United Kingdom: Results of a cross-sectional survey of the general population.
    Young T; Velikova G; Liegl G; Rose M; Nolte S;
    Eur J Cancer; 2024 Jun; 204():113927. PubMed ID: 38429166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psychometric properties of the EORTC QLQ-C30 in Uganda.
    Naamala A; Eriksson LE; Orem J; Nalwadda GK; Kabir ZN; Wettergren L
    Health Qual Life Outcomes; 2021 Apr; 19(1):131. PubMed ID: 33892718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The validation of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) in pre-operative patients with brain tumor in China.
    Cheng JX; Liu BL; Zhang X; Zhang YQ; Lin W; Wang R; Zhang YQ; Zhang HY; Xie L; Huo JL
    BMC Med Res Methodol; 2011 Apr; 11():56. PubMed ID: 21513533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. General population normative values for the EORTC QLQ-C30 by age, sex, and health condition for the French general population.
    Pilz MJ; Loth FLC; Nolte S; Thurner AMM; Gamper EM; Anota A; Liegl G; Giesinger JM;
    J Patient Rep Outcomes; 2024 May; 8(1):48. PubMed ID: 38695992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EORTC QLQ-C30 general population normative data for Italy by sex, age and health condition: an analysis of 1,036 individuals.
    Pilz MJ; Gamper EM; Efficace F; Arraras JI; Nolte S; Liegl G; Rose M; Giesinger JM;
    BMC Public Health; 2022 May; 22(1):1040. PubMed ID: 35610611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of the European Organisation for Research and Treatment of Cancer quality of life questionnaire module for older people with cancer: The EORTC QLQ-ELD15.
    Johnson C; Fitzsimmons D; Gilbert J; Arrarras JI; Hammerlid E; Bredart A; Ozmen M; Dilektasli E; Coolbrandt A; Kenis C; Young T; Chow E; Venkitaraman R; Howse F; George S; O'Connor S; Yadegarfar G;
    Eur J Cancer; 2010 Aug; 46(12):2242-52. PubMed ID: 20580993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Baseline functioning scales of EORTC QLQ-C30 predict overall survival in patients with gastrointestinal cancer: a meta-analysis.
    Zang Y; Qiu Y; Sun Y; Fan Y
    Qual Life Res; 2024 Jun; 33(6):1455-1468. PubMed ID: 38227073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30.
    King MT; Costa DS; Aaronson NK; Brazier JE; Cella DF; Fayers PM; Grimison P; Janda M; Kemmler G; Norman R; Pickard AS; Rowen D; Velikova G; Young TA; Viney R
    Qual Life Res; 2016 Mar; 25(3):625-36. PubMed ID: 26790428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validity and Reliability of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 - Tagalog among Adult Filipinos with Differentiated Thyroid Cancer.
    Bernardo DC; Li RJ; Jimeno C
    J ASEAN Fed Endocr Soc; 2018; 33(2):174-180. PubMed ID: 33442124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consistency matters: measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignancies.
    Sommer K; Cottone F; Aaronson NK; Fayers P; Fazi P; Rosti G; Angelucci E; Gaidano G; Venditti A; Voso MT; Baccarani M; Vignetti M; Efficace F
    Qual Life Res; 2020 Mar; 29(3):815-823. PubMed ID: 31782016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Body Composition and Biochemical Parameters of Nutritional Status: Correlation with Health-Related Quality of Life in Patients with Colorectal Cancer.
    Balderas-Peña LM; González-Barba F; Martínez-Herrera BE; Palomares-Chacón UR; Durán-Anguiano O; Salazar-Páramo M; Gómez-Sánchez E; Dávalos-Cobián C; Nava-Zavala AH; Hernández-Chávez GA; Sat-Muñoz D
    Nutrients; 2020 Jul; 12(7):. PubMed ID: 32708665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer.
    Mierzynska J; Taye M; Pe M; Coens C; Martinelli F; Pogoda K; Velikova G; Bjelic-Radisic V; Cardoso F; Brain E; Ignatiadis M; Piccart M; Van Tienhoven G; Mansel R; Wildiers H; Bottomley A;
    Eur J Cancer; 2020 Jan; 125():69-82. PubMed ID: 31838407
    [TBL] [Abstract][Full Text] [Related]  

  • 39. International phase IV validation study of an EORTC quality of life questionnaire for testicular cancer patients: the EORTC QLQ-TC26.
    Sztankay M; Aaronson NK; Arraras JI; Basso U; Bumbasirevic U; Efficace F; Giesinger JM; Johnson CD; van Leeuwen M; Oberguggenberger AS; Sosnowski R; Young T; Holzner B;
    BMC Cancer; 2018 Nov; 18(1):1104. PubMed ID: 30419889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice.
    Lorusso D; Colombo N; Herraez AC; Santin AD; Colomba E; Miller DS; Fujiwara K; Pignata S; Baron-Hay SE; Ray-Coquard IL; Shapira-Frommer R; Kim YM; McCormack M; Massaad R; Nguyen AM; Zhao Q; McKenzie J; Prabhu VS; Makker V
    Eur J Cancer; 2023 Jun; 186():172-184. PubMed ID: 37086595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.